title: A method for predicting target drug efficiency in cancer based on the analysis of signaling pathway activation.
abstract: A new generation of anticancer therapeutics called target drugs has quickly developed in the 21st century. These drugs are tailored to inhibit cancer cell growth, proliferation, and viability by specific interactions with one or a few target proteins. However, despite formally known molecular targets for every "target" drug, patient response to treatment remains largely individual and unpredictable. Choosing the most effective personalized treatment remains a major challenge in oncology and is still largely trial and error. Here we present a novel approach for predicting target drug efficacy based on the gene expression signature of the individual tumor sample(s). The enclosed bioinformatic algorithm detects activation of intracellular regulatory pathways in the tumor in comparison to the corresponding normal tissues. According to the nature of the molecular targets of a drug, it predicts whether the drug can prevent cancer growth and survival in each individual case by blocking the abnormally activated tumor-promoting pathways or by reinforcing internal tumor suppressor cascades. To validate the method, we compared the distribution of predicted drug efficacy scores for five drugs (Sorafenib, Bevacizumab, Cetuximab, Sorafenib, Imatinib, Sunitinib) and seven cancer types (Clear Cell Renal Cell Carcinoma, Colon cancer, Lung adenocarcinoma, non-Hodgkin Lymphoma, Thyroid cancer and Sarcoma) with the available clinical trials data for the respective cancer types and drugs. The percent of responders to a drug treatment correlated significantly (Pearson's correlation 0.77 p = 0.023) with the percent of tumors showing high drug scores calculated with the current algorithm.
authors: Pathway Pharmaceuticals, Wan Chai, Hong Kong, Hong Kong SAR.|D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
authors: Artem
authors: A
authors: Artemov
authors: D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.|First Oncology Research and Advisory Center, Moscow, Russia.
authors: Alexander
authors: A
authors: Aliper
authors: Pathway Pharmaceuticals, Wan Chai, Hong Kong, Hong Kong SAR.
authors: Michael
authors: M
authors: Korzinkin
authors: Pathway Pharmaceuticals, Wan Chai, Hong Kong, Hong Kong SAR.
authors: Ksenia
authors: K
authors: Lezhnina
authors: Department of Genetics, Genomics, and Informatics, University of Tennessee Health Science Center, Memphis, TN, USA.
authors: Leslie
authors: L
authors: Jellen
authors: D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.|First Oncology Research and Advisory Center, Moscow, Russia.|Pirogov Russian National Research Medical University, Department of Oncology, Hematology and Radiotherapy, Moscow, Russia.
authors: Nikolay
authors: N
authors: Zhukov
authors: D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.|Pirogov Russian National Research Medical University, Department of Oncology, Hematology and Radiotherapy, Moscow, Russia.
authors: Sergey
authors: S
authors: Roumiantsev
authors: Moscow State University, Faculty of Fundamental Medicine, Moscow, Russia.
authors: Nurshat
authors: N
authors: Gaifullin
authors: Insilico Medicine, Inc., ETC, Johns Hopkins University, Baltimore, MD, USA.
authors: Alex
authors: A
authors: Zhavoronkov
authors: First Oncology Research and Advisory Center, Moscow, Russia.
authors: Nicolas
authors: N
authors: Borisov
authors: Pathway Pharmaceuticals, Wan Chai, Hong Kong, Hong Kong SAR.|D. Rogachyov Federal Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.|Group for Genomic Regulation of Cell Signaling Systems, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.
authors: Anton
authors: A
authors: Buzdin
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002986:Clinical Trials as Topic; D019295:Computational Biology; D030541:Databases, Genetic; D055808:Drug Discovery / Q000379:methods*; D004789:Enzyme Activation; D020869:Gene Expression Profiling / Q000379:methods; D020022:Genetic Predisposition to Disease; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D018579:Patient Selection; D010641:Phenotype; D057285:Precision Medicine; D011237:Predictive Value of Tests; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015203:Reproducibility of Results; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases
keywords: bioinformatic modeling; cancer; intracellular signaling pathway; personalized medicine; response to target drug therapy